Loading…
Reported covered position: not applicable
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2026 · second_quarter · Q2
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Source: Senate LDA
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
FDA Reauthorization Act of 2017
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
21st Century Cures Act
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
21st Century Cures Act
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
21st Century Cures Act
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Mandate Oil Spill Investigations and Emergency Rules (MOSIER) Act of 2016
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Small Manufacturer Protection Act of 2013
Client: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION · Firm: PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Filing targets: Bureau of Industry and Security (BIS)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2026 · first_quarter · Q1
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2025 · fourth_quarter · Q4
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2025 · third_quarter · 3A
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, State, Dept of (DOS)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2025 · third_quarter · Q3
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2025 · second_quarter · Q2
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2025 · first_quarter · Q1
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and robustness of biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and robustness of biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and robustness of biopharmaceutical supply chains
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2024 · fourth_quarter · Q4
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2024 · third_quarter · Q3
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2024 · second_quarter · Q2
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2024 · first_quarter · Q1
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2023 · fourth_quarter · Q4
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring, and biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring, and biopharmaceutical supply chains
Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring, and biopharmaceutical supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2023 · third_quarter · Q3
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, onshoring, and supply chains
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, onshoring, and supply chains
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, onshoring, and supply chains
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2023 · second_quarter · Q2
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2023 · first_quarter · Q1
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2022 · fourth_quarter · Q4
Pandemic preparedness Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
Pandemic preparedness Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
Pandemic preparedness Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2022 · third_quarter · Q3
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2022 · second_quarter · Q2
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2022 · first_quarter · Q1
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2021 · fourth_quarter · Q4
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing, workforce development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2021 · third_quarter · Q3
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2021 · second_quarter · Q2
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2021 · first_quarter · Q1
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
COVID-19 vaccine & therapeutic production, and pandemic protection. Pharmaceutical supply chain and domestic manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2020 · fourth_quarter · Q4
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2020 · third_quarter · Q3
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2020 · second_quarter · Q2
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2020 · first_quarter · Q1
Discussed potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2019 · fourth_quarter · Q4
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2019 · third_quarter · Q3
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2019 · second_quarter · Q2
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2019 · first_quarter · Q1
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2018 · fourth_quarter · Q4
Discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2018 · third_quarter · Q3
Answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2018 · second_quarter · Q2
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2018 · first_quarter · Q1
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2017 · fourth_quarter · Q4
Lobbied for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2017 · third_quarter · Q3
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2017 · second_quarter · Q2
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), and provided general education about the pharma/biopharma contract services sector.
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2017 · first_quarter · Q1
Reauthorization of the Generic Drug User Fee Amendments, and general education about the pharma/biopharma contract services sector.
Reauthorization of the Generic Drug User Fee Amendments, and general education about the pharma/biopharma contract services sector.
Reauthorization of the Generic Drug User Fee Amendments, and general education about the pharma/biopharma contract services sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2016 · second_quarter · Q2
Gave presentation on pharma/biopharma contract manufacturing sector to Janet Woodcock, M.D., director of FDA/CDER Gave presentation on pharma/biopharma contract manufacturing sector to Congressional Life Science Caucus Met w/office of Rep. Juan Vargas (CA-51) to discuss Rare Disease Fund Act
Gave presentation on pharma/biopharma contract manufacturing sector to Janet Woodcock, M.D., director of FDA/CDER Gave presentation on pharma/biopharma contract manufacturing sector to Congressional Life Science Caucus Meeting w/office of Rep. Juan Vargas (CA-51) to discuss Rare Disease Fund Act
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2016 · first_quarter · Q1
Attended Senate HELP hearing on Generic Drug User Fee issues
Attended Senate HELP hearing on Generic Drug User Fee issues
Filing targets: SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2015 · second_quarter · Q2
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2015 · first_quarter · Q1
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
2015 · first_quarter · RR
Generic and Prescription Drug User Fee Amendment (GDUFA & PDUFA) reauthorization; R&D tax credit; serialization under DSCSA; FDA oversight
Generic and Prescription Drug User Fee Amendment (GDUFA & PDUFA) reauthorization; R&D tax credit; serialization under DSCSA; FDA oversight
Generic and Prescription Drug User Fee Amendment (GDUFA & PDUFA) reauthorization; R&D tax credit; serialization under DSCSA; FDA oversight
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Filing targets: HOUSE OF REPRESENTATIVES, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Lobbied for timely passage of FDA Reauthorization Act (H.R. 2430, S. 934), for changes to proposed OTC Monograph Safety, Innovation and Reform Act of 2017, and for potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Gave presentation on pharma/biopharma contract manufacturing sector to Janet Woodcock, M.D., director of FDA/CDER Gave presentation on pharma/biopharma contract manufacturing sector to Congressional Life Science Caucus Met with office of Rep. Juan Vargas (CA-51) to discuss Rare Disease Fund Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period H.R. 6, 21st Century CURES Act - discussed addition of small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 3631 - Small Manufacturer Protection Act - gives FDA Commissioner authority to issues small business waivers and reductions for User Fees under the Generic Drug User Fee Amendments (GDUFA) S. 3187 - Food and Drug Administration Safety and Innovation Act (FDASIA) - discussed reauthorization of Generic Drug User Fee Amendment after initial five-year period
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Generic and Prescription Drug User Fee Amendment (GDUFA & PDUFA) reauthorization; R&D tax credit; serialization under DSCSA; FDA oversight